# AptarGroup, Inc. (ATR) Stock Analysis: Exploring a Robust 18.99% Potential Upside

- Link: https://www.directorstalkinterviews.com/aptargroup-inc-atr-stock-analysis-exploring-a-robust-18-99-potential-upside/4121268864
- Published: 2026-11-02T11:15:14+00:00
- Author: Madison Wilson

AptarGroup, Inc. (NYSE: ATR), a leader in the healthcare sector’s medical instruments
and supplies industry, presents an intriguing opportunity for investors seeking 
growth and value. With a market capitalization of $8.7 billion, AptarGroup designs
and manufactures innovative solutions for drug delivery and consumer product dispensing,
serving a diverse range of markets including pharmaceuticals, beauty, and food and
beverage.

The current stock price stands at $137.20, reflecting a modest increase of 0.05%
recently. The stock has traded within a 52-week range of $111.94 to $145.72, indicating
its relative stability and resilience in a volatile market. Notably, the stock’s
potential upside is pegged at 18.99%, as analysts project an average target price
of $163.25, with a top estimate reaching as high as $220.00.

AptarGroup’s valuation metrics reveal a forward P/E ratio of 22.21, aligning it 
with peers in the sector and suggesting reasonable expectations for future earnings
growth. However, investors should note the absence of trailing P/E and PEG ratios,
which might necessitate a deeper dive into the company’s earnings trajectory and
growth forecasts.

On the performance front, AptarGroup has achieved a 6.00% revenue growth, supported
by an EPS of $5.54. The company boasts a return on equity of 9.79%, reflecting efficient
use of shareholder capital. Free cash flow, a crucial indicator of financial health,
is recorded at $255.67 million, offering a buffer for continued investment and dividend
payouts.

Speaking of dividends, AptarGroup’s yield stands at 1.46%, with a payout ratio of
46.38%. This suggests a balanced approach, providing income to investors while retaining
capital for growth investments.

Analyst sentiment remains bullish, with seven buy ratings and two hold ratings, 
and no sell recommendations. This consensus underpins the stock’s potential for 
upward movement, further supported by technical indicators. The RSI (14) is at an
elevated 79.01, often interpreted as the stock being overbought, yet it could also
signal strong momentum. The MACD of 1.87, surpassing the signal line of 0.50, suggests
a positive trend continuation.

In terms of moving averages, AptarGroup trades above both its 50-day ($125.86) and
200-day ($126.95) moving averages, reinforcing its bullish trajectory. As AptarGroup
continues to innovate in its product offerings across global markets, its strategic
positioning in the pharma, beauty, and closures segments could serve as a catalyst
for sustained growth.

For investors, AptarGroup presents a compelling case of potential upside and solid
financial performance. As the company continues to expand its footprint and capitalize
on its core competencies, it remains a stock worth watching for those seeking a 
blend of growth, income, and innovation in the healthcare sector.

Share on:
